Belite Bio Starts Enrollment In Pivotal Lead Asset Study In Inherited Eye Disease

  • Belite Bio Inc BLTE commenced enrollment for the U.S. Phase 3 trial of LBS-008 in patients with Stargardt Disease (STGD1), a progressively blinding disease with no approved treatment.
  • LBS-008 is an orally-available, small molecule retinol-binding protein 4 (RBP4) antagonist that selectively reduces the delivery of vitamin A (retinol) to the eye, leading to a reduction of toxic vitamin A byproducts (bisretinoids) that have been implicated in the onset and progression of STGD1. 
  • Belite Bio is currently conducting a 2-year Phase 2 trial and a 2-year Phase 3 (DRAGON) trial of LBS-008 in adolescent STGD1 subjects.
  • Preliminary data from the Phase 2 trial at the first 6-month interval shows that 8 of the 13 patients (or 61.5%) recorded a gain in best-corrected visual acuity (BCVA) in at least one eye, including two patients who recorded a BCVA gain in both eyes. 
  • Belite Bio expects the next data readout in Q4 of 2022.
  • The Phase 3 (DRAGON) trial plans to enroll approximately 60 patients.
  • Belite Bio plans to initiate a Phase 2/3 trial for Dry Age-related Macular Degeneration in Q4 of 2022.  
  • Price Action: BLTE shares are up 16.5% at $26.30 on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareSmall CapMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!